Acceptable and unacceptable procedures in bioavailability and bioequivalence trials

Pharmacological Research

Volumn 38, Issue 5, 1998, Pages 401-404

  Marzo, Antonio ^a   Ceppi Monti, Nunzia ^a  

^a IPAS SA   (Switzerland)

Author keywords

Bioavailability; Bioequivalence; Operating guidelines; Pharmacokinetic parameters; Statistical analysis

Indexed keywords

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; COMPARTMENT MODEL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DEVELOPMENT; EUROPEAN UNION; FOOD AND DRUG ADMINISTRATION; PHARMACOKINETICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; UNITED STATES;

EID: 0032212920     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.1998.0380     Document Type: Article

References (17)

1. 1. US Food and Drug Administration. Bioavailability and bioequivalence requirements. Fed. Register 1977; 42: 1638-53.
2. 2. US Pharmacopeia 23. National formulary Supplement N° 5. In vivo bioequivalence guidances, 1996: 3490-531.
3. 3. EU Note for guidance: Investigation of bioavailability and bioequivalence. The Regulatory Affairs Journal III, Addendum 2, 1992.
4. 4. Marzo A, Balant LP. The bioequivalence: an updated reappraisal addressed to applications of interchangeable multi-source pharmaceutical products. Arzneim Forsch 1995; 45: 109-15
5. 5. Marzo A, Scaglione F. Farmacocinetica e metabolismo dei farmaci. In: Manuale di chemioterapia. Fraschini F, Nicolin A. eds. Casa Editrice Ambrosiana, 3rd edition, 1995: 83-96.
6. 6. Marzo A, Ceppi Monti N. Quale modello nell'analisi farmacocinetica di studi di biodisponibilità e bioequivalenza? Boll Chim Farm 1998; 137: 69-73.
7. 7. Marzo A. Pharmacokinetic analysis, bioavailability and operating guidelines. J Pharm Pharmacol 1997; 49: 1259-60.
8. 8. Olkkola KT, Brunetto AV, Mattila MJ. Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. Clin Pharmacokinet 1994; 26: 107-20.
9. 9. Schentag JJ, Cerra FB, Calleri GM, Leising ME, French MA, Bernhard H. Age, disease and cimetidine disposition in healthy subjects and chronically ill patients. Clin Pharmacol Ther 1981; 29: 734-43.
10. 10. Marzo A. Clinical pharmacokinetic registration file for NDA and ANDA procedures. Pharmacol Res 1997; 36: 425-50.
11. 11. Marzo A, Rescigno A. Pharmacokinetics of endogenous substances: some problems and some solutions. Eur J Drug Metab Pharmacokinet 1993; 18: 77-88.
12. 12. Marzo A, Cardace G, Arrigoni Martelli E. Enzymes in stereoselective pharmacokinetics of endogenous substances. Chirality 1992; 4: 247-51.
13. 13. Marzo A, Curti S. L-carnitine moiety assay: an up-to-date reappraisal covering the commonest methods for various applications. J Chromatogr B 1997; 702: 1-20.
14. 14. Westlake W.J. Symmetrical confidence intervals for bioequivalence trials. Biometrics 1976; 32: 741-4.
15. 15. Steinijans VW, Hauschke D. International harmonisation of regulatory bioequivalence requirements. Clin Res Reg Affairs 1993; 10: 203-20.
16. 16. Schuirmann DJ. A comparison of the two one-sided tests procedures and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987; 15: 657-80.
17. 17. Marzo A. Open questions in bioequivalence. Pharmacol Res 1995; 32: 237-40.